ArticleDigestive diseases and sciences2026
CircRSF1 Promoted HepG2 Cell Proliferation, Migration and Invasion Depending on EIF4A3.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors, characterized by high recurrence and mortality rates. The inflammatory microenvironment plays a crucial role in cancer initiation and progression. The RSF1 gene, associated with hepatitis, generates circular RNA during transcription, which is intricately linked to liver diseases and inflammatory processes. We sought to explore the role of inflammation-related circRSF1, which may play an important role in the occurrence and development of HCC in vitro.
methodsWe successfully established an in vitro HCC progression model using IL-1β-treated HepG2 cells. CircRSF1 expression measured was in HCC tissue and IL-1β-treated HepG2 cells by quantitative RT‑PCR. EIF4A3 expression was detected by western blot. Cell proliferation assay was performed by cck-8 assay. Cell migration and invasion was performed by transwell assay. The binding relationship of circRSF1 and EIF4A3 was confirmed by RNA binding protein immunoprecipitation assay and RNA pull down assay. Role of circRSF1 and EIF4A3 in HCC progress in vivo was evaluated nude mouse xenograft model.
resultsIL-1β upregulated circRSF1 expression in HepG2 cells. Consistently, elevated circRSF1 levels were also observed in clinical HCC samples. Functional studies demonstrated that circRSF1 knockdown suppressed IL-1β-induced proliferation, migration, and invasion of HepG2 cells. Further mechanistic investigations revealed stable binding sites between circRSF1 and EIF4A3. Silencing EIF4A3 enhanced the biodegradation of circRSF1, suggesting that circRSF1 depends on EIF4A3 to maintain its stability. In vivo, knockdown of EIF4A3 reduced the tumor volume and weight, which was reversed by circRSF1 overexpression.
conclusionsOur findings indicate that circRSF1, stabilized by EIF4A3, promotes the malignant progression of HepG2 cells in vitro. These results suggest that circRSF1 may function as an oncogene in inflammation-mediated HCC progression, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
41843036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.